ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SCLP Scancell Holdings Plc

9.875
0.00 (0.00%)
09 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Scancell Holdings Plc LSE:SCLP London Ordinary Share GB00B63D3314 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 9.875 9.00 10.50 - 0.00 07:31:15
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 5.27M -11.94M -0.0129 -7.65 91.58M
Scancell Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SCLP. The last closing price for Scancell was 9.88p. Over the last year, Scancell shares have traded in a share price range of 7.65p to 18.125p.

Scancell currently has 927,819,977 shares in issue. The market capitalisation of Scancell is £91.58 million. Scancell has a price to earnings ratio (PE ratio) of -7.65.

Scancell Share Discussion Threads

Showing 36201 to 36224 of 66525 messages
Chat Pages: Latest  1449  1448  1447  1446  1445  1444  1443  1442  1441  1440  1439  1438  Older
DateSubjectAuthorDiscuss
29/1/2021
10:24
We all keep going on about Covid


As of January 24, 2021, Belgium had the highest rate of coronavirus deaths among its population in the European Economic Area at 181.89 deaths per 100,000 population. Slovenia has recorded 172 deaths from coronavirus per 100,000. Furthermore, the UK has the highest number of confirmed coronavirus deaths in Europe, at 97,939.

however

For the EU-27, the standardised death rate for cancer was 257.1 per 100 000 inhabitants

a Little perspective of the Value building in Scancell

inanaco
29/1/2021
09:48
On Novavax,

"In some positive news on the virus front, a fourth Covid-19 vaccine could be approved for use in the UK within weeks as late-stage trials suggested it was 89% effective in preventing coronavirus.
The UK has secured 60 million doses of the Novavax jab – to be produced on Teesside – which is believed to offer protection against the new UK and South African variants. It was shown to be 89% effective at preventing coronavirus in participants in its phase 3 clinical trial in the UK, which involved more than 15,000 people aged between 18-84, of which 27% were older than 65, Novavax said.

The vaccine will now be assessed by the Medicines & Healthcare Products Regulatory Agency, UK Prime Minister Boris Johnson confirmed. The jab has shown around 60% effectiveness against the South African variant, which has been worrying scientists due to concerns vaccines may not work against it, but it offered 86% protection against the new UK strain. "



Interesting to hear about SN15 and the new variants.

Cheers for the heads up there guys.

geckotheglorious
29/1/2021
09:06
need the clinical data ........ EE

then talk business ""but with the GOV""

inanaco
29/1/2021
09:02
Indeed, TF.I note that, whilst the Novavax vaccine is being trumpeted as an 89% success, the trials of their vaccine in South Africa show much reduced effectiveness. The SA variant appears to be undermining the effectiveness of all the vaccines at present, so it is still game-on to bring on a better vaccine, with longer-lasting and broader protection.The main thing I worry about on that is not the science. It is the lack of a big partner, capable of manufacturing at scale. Presumably phase 1 trials are a pivot point on this - but, as I understand the partnership group formation timing on existing vaccines, partnering prior to phase 1 shouldn't be impossible.What's the view of others on this point?
emptyend
29/1/2021
08:56
yet nobody picks up on it ........ TF ? why have you not posted this on the LSE it has a huge impact on the future of Covid vaccines


Importantly in this trial, approximately 1/3 of the patients enrolled (but not included in the primary analyses described above) were seropositive, demonstrating prior COVID-19 infection at baseline. Based on temporal epidemiology data in the region, the pre-trial infections are thought to have been caused by the original COVID-19 strain (i.e., non-variant), while the subsequent infections during the study were largely variant virus. These data suggest that prior infection with COVID-19 may not completely protect against subsequent infection by the South Africa escape variant, however, vaccination with NVX-CoV2373 provided significant protection.

... proof that the Virus can escape natural infection of the original Covid

inanaco
29/1/2021
08:53
It is .... what's changed is the Virus so it appears another SN ie SN15 has a broader spread with its VNABS that text i posted last night proves the SA variant can overcome past immunity ........

which means all the posts i have been Blabbing on about ref Manaus P1 new lineage means its even more dangerous than we thought

you can see a clear drop in efficacy of 10% in the vaccines trial against the SA variant

so these drops in efficacy are really important

inanaco
29/1/2021
08:52
EE - yes that'd be this ? (I didn't blink at first being steeped in the idea that SN14 was already the 'Bees Knees' and likely to cover all variants).

Thanks for the on-topic . . .

"In December 2020, we announced the selection of our lead COVID-19 vaccine candidate, SN14. In light of the newly identified variants of the SARS CoV-2 virus, which are becoming increasingly prevalent and which may become more important in the transmission and community spread of COVID-19, more recent data has suggested that another of our lead candidates, SN15 (or SCOV1 for future reference), may confer even better protection against the virus than SN14. SCOV1 reproducibly elicited higher-titre anti-S virus neutralising antibodies (VNAbs) together with high avidity T cells against both the S and N proteins and further studies are underway to test SCOV1 against the variants identified in South Africa and Brazil."

So now we can forget SN14 and it's SCOV1 for a triumph one day ?

torquayfan
29/1/2021
08:45
Anyone here noticed that the interims are out this morning....?One rather interesting detail on the Covidity front....
emptyend
29/1/2021
08:29
Tf

No Quicksand

""I was motivated by ideas that might have been of help.""

great then under each article in the Telegraph has a comments section ...

I am sure Panama7 is trying to do the same

""I was motivated by ideas that might have been of help.""

the problem is its on Here

a Scancell BB who are developing Vaccines not Face masks, etc

you can always argue how you could run the country better ........ indeed the EU thought they could with the Billions of Euro they have ... but we voted OUT .. do you get my point "crushing" "trapped" Brits don't like it

so its a balancing act .....

look at the vaccine take up by BAME dreadful ....

they are the worse affected by the virus and the least likely to vaccinate !!! so the Psychology of all these lockdowns etc play's a bigger role than you think

so unless you take in the whole .... which needs expertise from every part of the giant gearbox messing with one tooth has little effect

you see already when so called Experts have not had a coffee on the LSE ... then apply a pessimist head and all sorts of troubles start especially if that party is pushed forward as an expert by the few that don't have a clue

inanaco
29/1/2021
08:18
“We made a sad mistake in the beginning of this campaign, which may yet prove fatal to us. In the beginning all the worst generals were appointed to command our armies and all our best generals to edit the newspapers. As you know, I have planned some campaigns and fought quite a few battles. I have given the work all the thought I could, and sometimes when my plans were completed, so far as I could see, they seemed perfect. But when I have fought them through, I have discovered defects and occasionally wondered I did not see some of the faults in advance. When it was all over I found, just by the simple process of reading a newspaper, that those ‘best editor’ generals saw all the defects plainly from the start. Unfortunately, they did not communicate their knowledge to me until it was too late to correct my ignorance.”


Robert E Lee

goyathlay
29/1/2021
06:00
Hi Inan. Thanks for your 36316 which was digestible in part. Taking some points in turn:-

"Both Countries US and UK are vaccinating at a pace ......... you cannot stop Variants or new linage they can appear spontaneous in any country because it gives "advantage" and that then becomes dominate in that region hence the 501 mutation appears in many variants Brazil, SA and the UK". Makes sense - no problem.

"which is why just closing the borders will not stop transmission" - agreed - I never said that myself, usually noting 'every little helps' in fact.

"thailand is desperate to control covid because it does not have the infrastructure to deal with 70,000 cases per day the UK has managed it" - every Country is desperate to control Covid actually. 70,000 cases a day would be a problem anywhere. You say the UK has 'managed it' - Ha Ha! The UK has actually 'managed' around the highest rate of deaths in the World emulating the levels in major Countries such as the USA and Brazil, (say no more) - have they 'managed it' too ?

"Death rates are because of this new Variant and its transmit ability if that variant appears in Thailand they may be in serious trouble with track and trace overwhelmed". The death rates in the UK ranked similarly highly before the new variants appeared - the point of 'every little helps' factors like curfews, masks, border controls, all the factors you have been wrong about throughout, is that they help reduce the rate of infection. Yes track and trace is easier the fewer the cases you have - join the dots ?

Then your rambling 'diss' machine takes over - I see the whole picture quite as clearly as you do - a seat on SAGE would have been fun but it's not a qualification to post here is it ? I was never trying to run a beauty competition on Covid control measures, (as it has suited 'Goandslay' and yourself to imply), I was motivated by ideas that might have been of help.

As for blame, I just tell it as I see it. To recap - this Govt, high on it's Brexit 'triumph' and 80 seat majority, was late to react and they also underestimated the threat from Covid - that's after weeks watching the pandemic tragically unfold in Italy and Spain. However, FULL CREDIT to BJ and Co. for the decisions on vaccine development and manufacture.

Quicksand coming - I just know ! BFN

torquayfan
29/1/2021
00:48
Importantly in this trial, approximately 1/3 of the patients enrolled (but not included in the primary analyses described above) were seropositive, demonstrating prior COVID-19 infection at baseline. Based on temporal epidemiology data in the region, the pre-trial infections are thought to have been caused by the original COVID-19 strain (i.e., non-variant), while the subsequent infections during the study were largely variant virus. These data suggest that prior infection with COVID-19 may not completely protect against subsequent infection by the South Africa escape variant, however, vaccination with NVX-CoV2373 provided significant protection.

... proof that the Virus can escape natural infection of the original Covid

inanaco
28/1/2021
23:52
Gecko - I enjoyed this in your 36258 - "I'd have shut flights in Jan/Feb 2020 from China, Italy, Europe.."
torquayfan
28/1/2021
21:56
Novavax data

Novavax today published positive data from the UK phase 3 study of its COVID-19 vaccine candidate, showing it to be 89.3% effective in preventing coronavirus in participants.




'First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants'

goyathlay
28/1/2021
17:29
LMFAO Gecko

Parole? That implies that being filtered by some conspiracy-theorising, quarter-wit like you is some kind of punishment. You are a cowardly nothing and your comments are worthless.

No peaking (sic) now!

goyathlay
28/1/2021
16:00
Does that chart look like an inverse head and shoulders to anybody else ?
miavoce
28/1/2021
15:57
Thanks Inanaco.
miavoce
28/1/2021
15:56
not from my end, but far more detail on the way they investigated Modi-1
questions at end are interesting considering the audience was science based

have to wait for the trial but it does give you an insight on why it should work
and the reasoning behind it .

inanaco
28/1/2021
15:12
Any new insights Inanaco ?
miavoce
28/1/2021
15:04
400 watchers

not bad eh! lindy Good stuff and in far more detail, good questions at end well worth watching

inanaco
28/1/2021
14:44
cant see a record button ........
inanaco
28/1/2021
14:32
'Coronavirus: Germany may limit AstraZeneca jab to under-65s'



Presumably they won't need quite so many then.

goyathlay
28/1/2021
14:06
Inn - I have to go out so am going to miss it. If there is a recording facility could you do and post a link here for me later.
Thanks

moljen
28/1/2021
14:03
lindy on soon
inanaco
Chat Pages: Latest  1449  1448  1447  1446  1445  1444  1443  1442  1441  1440  1439  1438  Older

Your Recent History

Delayed Upgrade Clock